InvestorsHub Logo
Followers 1
Posts 27
Boards Moderated 0
Alias Born 02/06/2013

Re: august1991 post# 18858

Wednesday, 10/23/2013 1:48:10 PM

Wednesday, October 23, 2013 1:48:10 PM

Post# of 424862
IMHO AMRN isn't dropping significantly on this news because it's already armageddon priced. Currently, AMRN's market cap is at $300MM plus. Kindly note GSK bought Reliant (developers of Lovaza) for $1.6 billion. Vascepa is generally regarded as a superior drug to Lovaza which currently earns close to $1 billion per year (in the Marine indication plus off-label). To put a roughly equivalent valuation on AMRN would require the share price to be at $9.27 today (not including potential Anchor indication plus other possible markets). To put it succinctly AMRN is very undervalued barring some unforeseen catastrophe.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News